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Implantable cardioverter defibrillators (ICDs) provide a safeand effective treatment for life-threatening ventricular ar-rhythmias. Several investigators have demonstrated that ICDuse in pediatric patients is feasible, effective, and associated
with a low risk of sudden death in follow-up.1 However, ICD
placement in young children can usually be accomplished only by
a thoracotomy approach involving multiple incisions and place-
ment of epicardial defibrillation electrodes. We describe a less
invasive yet efficacious lead configuration likely to be associated
with a lower complication rate.
Clinical Summary
A 3.5-year-old, 17.5-kg, previously healthy boy came to the emer-
gency department of a referring hospital in status epilepticus. He
was found to be in ventricular fibrillation, which responded to
external defibrillation. He was resuscitated and treated with a
lidocaine infusion and phenytoin. He made a full neurologic re-
covery and was transferred to our institution for further manage-
ment. There was no family history of cardiac disease. His physical
examination, electrocardiography, echocardiography, and cardiac
magnetic resonance imaging results were normal. A decision was
made to implant an ICD for this episode of aborted sudden death.
Because of his age, size, and probable lifelong need for defibril-
lation, the decision was made to place a single subcutaneous
defibrillation lead and “active can” configuration.
In the operating room, with the patient under general anesthe-
sia, the apex of the heart was exposed through a subxiphoid
incision. A Medtronic 7841 epicardial bipolar pacing lead
(Medtronic, Inc, Minneapolis, Minn) was placed on the apex of the
right ventricle, and adequate pacing and sensing thresholds were
obtained. The Medtronic 6996 T tunneling tool was shaped ac-
cording to the anatomy of the patient and placed in the introducer
sheath, which was then used to create a subcutaneous tunnel. The
tunnel was created by blunt dissection at the level of the seventh
intercostal space and extended posteriorly adjacent to the spine.
The creation of the tunnel was guided by the anesthesiologist,
directly palpating the lead and anatomic landmarks. This maneuver
was used to position the tip of the lead as close to the spine as
possible. Previous studies have demonstrated that the most effi-
cient defibrillation vector is achieved by placing the lead between
the sixth and tenth intercostal spaces with the tip as close to the
spine as possible.2 The Medtronic model 6996 SQ lead (Figure 1)
was advanced in the sheath. The distal end of the lead has a 25-cm
long defibrillation coil with an exposed metal surface area of 5 cm2
and an electrical shadow area of 18 cm2. The introducer sheath was
slit open and removed with the stylet and wire. A preperitoneal
abdominal pocket was created in the right upper quadrant for a
Medtronic Marquis 7274 ICD device. The leads were secured in
the appropriate ports and the device was interrogated (Figure 2).
After confirmation of adequate sensing, defibrillation threshold
(DFT) testing was performed. Ventricular fibrillation was induced
with a T-wave shock, and defibrillation was successfully achieved
twice with a 16-J biphasic shock. Lower energies were not tested
and the device was programmed as a single-zone ventricular
fibrillation device programmed to deliver initial therapy of 20 J
and five rescue shocks of 30 J each. A pericardial drain was placed
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Figure 1. Medtronic model 6996 SQ lead. Note coils of 25-cm long
defibrillation electrode at distal tip of lead.
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and the incisions were closed. An epidural catheter was placed to
provide analgesia. The patient was extubated and transferred to the
cardiac intensive care unit. The drain was removed on the first
postoperative day. The epidural infusion was discontinued on the
second postoperative day. The child was discharged to home on
the third postoperative day. He is free of symptoms 5 months after
discharge. Repeated DFT testing has been planned for 6 months
after implantation.
Discussion
ICD placement with epicardial leads implanted through a thora-
cotomy approach has been associated with high incidences of both
acute and chronic complications in both pediatric and adult pa-
tients.3 To overcome these issues, transvenous defibrillation leads,
biphasic waveforms, and pectoral implantation of active can de-
vices were developed.4-6 However, widespread use of the trans-
venous ICDs in young patients has been limited by mismatch
between patient size and size of defibrillation leads, lack of access
to the right ventricle in patients with complex congenital heart
disease, and increasing paucity of venous access in patients requir-
ing lifelong device therapy.
The subcutaneous array was developed as an adjunct to a
transvenous ICD lead in an effort to provide an increased safety
margin in adult patients with high DFTs. Adult studies have
demonstrated that the array is at least as effective as an active can
or subcutaneous patch in lowering high DFTs.6,7 Moreover, sub-
cutaneous arrays have been associated with a lower incidence of
side effects than are subcutaneous patches.8 There are no reports in
the adult literature about the use of the subcutaneous array with an
active can without a transvenous defibrillation electrode. However,
two recent pediatric case reports and an animal study have docu-
mented the successful use of this configuration in children and
young animals.9,10 With limited follow- up, neither reported any
complications of the procedure.
Standard subcutaneous array leads have three fingers and re-
quire extensive dissection with creation of three subcutaneous
tunnels for placement. However, at least one case series demon-
strated that the two-finger array is as efficacious as the triple-finger
subcutaneous array configuration in lowering DFTs when used as
an adjunct to a transvenous defibrillation electrode.9 In another
study of adult patients, investigators have demonstrated that ele-
vated DFTs may be significantly decreased with the addition of a
single subcutaneous lead to a right ventricular lead active can
defibrillation configuration.2 The subcutaneous lead is easy to
implant, allows flexible lead positioning, and has a long defibril-
lation coil (25 cm) with a small lead caliber (7.5F). Because of the
size of the child, a single subcutaneous lead was used as the anode
with an active can as the cathode. This configuration achieved
successful defibrillation with low DFTs. This technique, though
still requiring placement of an epicardial pacing and sensing lead,
requires a single incision that minimizes the surgical approach and
may be successfully used in younger and smaller patients with
minimal complications. Addition of a second finger to create a
subcutaneous array or a patch electrode may be used to lower
DFTs as the patient grows. Our case represents use of an innova-
tive minimally invasive technique by which internal defibrillation
may be achieved in small and young patients. Additional follow-up
is necessary to determine both the stability of the defibrillation
thresholds and any long-term complications that maybe associated
with this procedure.
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